ADAP
Adaptimmune Therapeutics
ADAP
ADAP
69 hedge funds and large institutions have $166M invested in Adaptimmune Therapeutics in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.51% less ownership
Funds ownership: 12.1% → 11.59% (-0.51%)
30% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 23
Holders
69
Holding in Top 10
1
Calls
$81K
Puts
$4K
Top Buyers
| 1 | +$5.41M | |
| 2 | +$3.66M | |
| 3 | +$721K | |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$599K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$466K |
Top Sellers
| 1 | -$6.54M | |
| 2 | -$1.89M | |
| 3 | -$644K | |
| 4 |
Goldman Sachs
New York
|
-$444K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$398K |